Applied Therapeutics Reports Second Quarter 2023 Financial Results

Regulatory progress for govorestat for the treatment of Classic Galactosemia, with potential NDA submission based on discussions with the FDA as well as EMA Marketing Authorization Application...
-Today at 07:04 am- MarketScreener

Related Keywords

United States ,American ,Advanz Pharma ,Shoshana Shendelman ,Maeve Conneighton ,Peripheral Nerve Society Annual Meeting ,Therapeutics Inc ,Meeting Of The American Diabetes Association ,Drug Administration ,Twitter ,Meeting Of The Peripheral Nerve Society ,European Medicines Agency ,Nasdaq ,Exchange Commission ,Classic Galactosemia ,Authorization Application ,Sorbitol Dehydrogenase ,Diabetic Cardiomyopathy ,Chief Executive Officer ,United States Food ,Pre New Drug Application ,Applied Therapeutics ,Pediatric Investigational Plan ,Baseline Data ,Ongoing Phase ,American Diabetes Association ,Clinical Trial Design ,Sorbitol Reduction Interim Analysis ,Nerve Society Annual ,Peripheral Nerve ,Annual Meeting ,Peripheral Nerve Society ,Medicinal Product Designation Granted ,Orphan Medicinal Product Designation ,Preclinical Data Published ,Deficient Patient Derived Cells ,Drosophila Disease Model Treated ,Clinical Investigation ,Aldose Reductase Inhibitor ,Private Securities Litigation Reform Act ,Markets ,